Skip to main content
. 2023 Jun 5;29(6):1400–1411. doi: 10.1038/s41591-023-02399-0

Extended Data Fig. 3. Clinical outcomes of ovarian cancer patients treated with camonsertib.

Extended Data Fig. 3

(a) Duration of treatment. (b) Kaplan–Meier estimate for progression-free survival. Median progression-free survival was 35 weeks. RECIST, Response Evaluation Criteria in Solid Tumors.